Subsequent to the publication of the previous paper entitled "*Pneumococcal Conjugate Vaccines and Otitis Media: An Appraisal of the Clinical Trials,*" scientific errors were discovered in Table 4. Therefore, an erratum was submitted with corrections to the table.

###### 

Vaccine efficacy values in the long-term followup of PCV clinical trials with otitis media as an endpoint \[3, 13\]. Adapted with permission from Fletcher and Fritzell, 2007 Elsevier Ltd. All rights reserved \[7\].

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                   Follow-up clinical trials                                                      
  ------------------------------------------------ ------------------------------------------------------- ---------------------- ------------------------------------
  Study vaccine                                                                                            PCV7-CRM               PCV7-CRM

  Period                                                                                                   1998-1999              1999--2001

  Number                                                                                                   27,754                 756

  Age                                                                                                      Until aged 3.5 years   Until aged 4-5 years

                                                                                                                                  

                                                   Clinical endpoints^*∗*^: vaccine efficacy, % (95% CI)                          

                                                                                                                                  

  Otitis media visits (NCKP) or episodes (FinOM)   PP                                                      8 (5--11)              8 (−2 to 16)

  ITT                                              7 (5--9)                                                ---                    

  Recurrent otitis media^*∗∗*^                                                                                                     

   3/4                                                                                                     10 (7--13)             18 (1--32); 50 (15--71)^†^

   5/6                                                                                                     ---                    ---

   ≥10^‡^                                                                                                  26 (12--38)            ---

  All tympanostomy-tube placements                                                                         23 (−10 to 46)         39 (4--61)^§^; 49 (−7 to 76)^§†^ \
                                                                                                                                  44 (19--62)^¶^; 63 (28--81)^¶†^

  Rate of AOM-related ambulatory visits                                                                    8 (5--10)              ---

  Rate of antibiotic prescriptions for AOM                                                                 6 (4--7)               ---
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

^*∗*^See Table  1 for primary otitis media endpoint, otitis media definition, myringotomy criteria, and source of MEF in each study.

^*∗∗*^Number of episodes in 6 months/number of episodes in 1 year.

^†^In children diagnosed with "chronic otitis media with effusion."

^‡^Efficacy against 10 or more episodes within 6 months.

^§^Primary analysis set (see Section  3.5.2. FinOM vaccine trial).

^¶^Secondary analysis set (see Section  3.5.2. FinOM vaccine trial).

Reported values are rounded to whole numbers; dash line indicates not reported.

CI: confidence interval; ITT: intent to treat; PP: per-protocol.
